Clinical Research Directory
Browse clinical research sites, groups, and studies.
Laser Photocoagulation and Ranibizumab Treatment in Proliferative Diabetic Retinopathy
Sponsor: Aswan University
Summary
To evaluate the effects of PRP as monotherapy or with combination of intravitreal Ranibizumab injection on microvascular density changes of the macula of eyes with PDR using OCTA
Official title: Pan-Retinal Photocoagulation With Intravitreal Ranibizumab In Treatment Of Proliferative Diabetic Retinopathy
Key Details
Gender
All
Age Range
30 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2023-07-01
Completion Date
2025-07-31
Last Updated
2026-09-15
Healthy Volunteers
No
Conditions
Interventions
Ranibizumab 0.5 mg
Groupe (1) included eyes that underwent laser photocoagulation (PRP) in two sessions 1week apart, and group (2), included eyes that were treated with laser photocoagulation (PRP) combined with intravitreal anti VEGF (ranibizumab 0.5 mg) injection one week before PRP, which was also performed in two sessions 1 week apart
laser photocoagulation (PRP)
photocoagulation was performed through a contact lens (Ocular Mainster PRP 165, Ocular Instruments, Bellevue, WA, USA) using double frequency YAG, 532 nm (Ellex Medical Pty Ltd. 3-4 Second Ave, Mawson Lakes SA 5095, Australia) with a 200-µm spot diameter and a 100 m-s pulse duration. The power of the laser was individually adjusted to produce yellowish-white coagulative spots. PRP was performed by a single retina specialist in 2 sessions with an interval of 1 week in-between with a total number of 1500-3000 burns
Locations (1)
Aswan University hospital
Aswān, Aswan Governorate, Egypt